News | Press Releases | NuView Life Sciences | NuView Life Sciences

Targeting genomic VPAC receptors in voided urine for confirmation of benign prostatic hyperplasia

Sat, 04 May 2024 19:06:03 GMT

New breakthrough in the fight against Prostate Cancer

BJUI COMPASS Abstract / February 12, 2024 Objectives: The objective of this study is to validate a hypothesis that a non-invasive optical imaging assay targeting genomic VPAC receptors on malignant cells shed in voided urine will represent either benign prostatic hyperplasia (BPH) or prostatic can-cer (PCa). Risk for BPH in men 50–70 years old is 50–70% and PCa is 17%. BPH and PCa can coexist in 20% of men with BPH. Most commonly practiced methods to diagnose BPH do not distinguish BPH from PCa.

Patients (or Materials) and Methods: Males with BPH (N = 97, 60.8 ± 6.3 years, prostate-specific antigen 0.7 ± 0.4 ng/mL) and without oncologic disease (N = 35, 63.4 ± 5.8 years, prostate-specific antigen < 1.5 ng/mL) signed informed consent form and provided voided urine. Urine was cytocentrifuged, cells collected on glass slide, fixed, treated with VPAC specific fluorophore TP4303 (Kd 3.1 108M), washed, incubated with DAPI and observed using a fluorescence microscope. Cells with no VPAC did not fluoresce (BPH) and those with VPAC had red-orange fluores-cence (PCa). Real-time polymerase chain reaction analyses for VPAC and NKX3.1 assay for cell origin were performed.

Results: Eighty-seven subjects were negative for VPAC expression. Positive VPAC expression was noted in 10 subjects. Patient chart review for clinical data on these 10 VPAC positive subjects showed five had nephrolithiasis, three had renal cysts, one had prostatitis and one was being treated with finasteride. Real-time polymerase chain reaction analysis-VPAC expressions for 7 normal and 12 BPH subjects were 1.31 ± 1.26 and 0.94 ± 0.89, respectively (P = 0.46). NKX3.1 showed cells of pros-tate origin for finasteride-treated patient. Specificity for VPAC urine assay for exclud-ing prostate cancer in this BPH cohort was 88.5%, positive predictive value 0.00%and negative predictive value 100%.

Conclusion: VPAC assay may contribute extensively for BPH diagnosis and warrant continued investigation.

Read Full Article ….

NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer

NuView Life Sciences

NuView Announces Two Appointments to Board of Directors

Wed, 03 Jan 2024 23:25:56 GMT

NuView Life Sciences Announces the Appointments of Dr. Stanley J. Pappelbaum and A.J. Boechler to Board of Directors

Two Additional Board Appointments Expected in 2024 as NuView Advances Pipeline of Theranostic Radiopharmaceuticals for Various Cancers

PARK CITY, UT / PR Newswire / January 3, 2024 / -- NuView Life Sciences, Inc. ("NuView", the "company"), a radiopharmaceutical company seeking to enhance the global oncology market with its novel platform (NV-VPAC1™) capable of detecting and precisely targeting G protein-coupled receptors for cancer, announced the appointments of Dr. Stanley J. Pappelbaum and A.J. Boechler to its board of directors. Their combined experience and expertise developing, commercializing, and scaling therapeutics that span the product lifecycle adds further depth to NuView’s leadership team as the Company advances its NV-VPAC1™ theranostic technology towards key clinical and commercialization milestones in 2024. NuView is leveraging its NV-VPAC1™ platform to advance a pipeline of precision in vitro laboratory diagnostics tests and in vivo cancer diagnostics and therapy delivery systems targeting multiple high-need, large-market indications, including prostate and bladder cancer.

“On behalf of the Board, I am pleased to welcome Stan and A.J. and look forward to benefitting from their knowledge and expertise,” said Paul Crowe, Chairman and Chief Executive Officer of NuView. “They join our board of directors at a pivotal time for NuView as we plan to initiate clinical trials in early 2024 of NV-VPAC1™ Liquid Biopsy Diagnostic Test, our precision in vitro laboratory diagnostics test for detecting tumor cells in biological fluid. Additionally, their strategic planning and insight will be invaluable as we advance our NV-VPAC1™ Theranostics Platform that combines the diagnostic acuity of Copper-64 (Cu-64) with the precision therapeutic intervention of Copper-67 (Cu-67).”

Stanley J. Pappelbaum, MD, SM, FAAP, FACC, is a La Jolla, California-based strategic healthcare consultant who advises hospitals, medical groups, and biomedical research entities across the United States. Dr. Pappelbaum began his career as a pediatric cardiologist at the University of California, San Diego School of Medicine and San Diego Rady Children’s Hospital, where he led the establishment of a comprehensive children’s cardiac center throughout an area serving 5 million Southern Californians. His role as CEO of Scripps Health system leading five hospitals in San Diego County and the subsequent launch of Pappelbaum Turner Healthcare Consulting highlight his expertise guiding complex healthcare organizations. In addition to his medical credentials, Dr. Pappelbaum earned a master’s degree in management with a health focus at the Sloan School of Management at Massachusetts Institute of Technology.

A.J. Boechler joins the NuView board offering more than 30 years of executive leadership experience at the General Electric Company. His expertise spans multiple business models, global operations, sales and marketing, and P&L leadership. A.J. spent 10 years in GE Healthcare where he expanded the business footprint in the U.S. with the launch of functional imaging (PET), radiopharmacy (cyclotron), and 3T MRI product lines. A.J. applied his leadership skills in additional global business roles at GE Plastics, GE Lighting, GE Fanuc Automation, and GE Oil and Gas. His global tenure in sales, marketing, consulting, manufacturing, and digital transformation showcases his ability to steward complex teams and successfully execute business strategies to deliver results on a global scale. Mr. Boechler holds a Bachelor of Arts in Business Administration from California State University, Long Beach.

----------

NuView’s NV-VPAC1™ Liquid Biopsy Diagnostic Test clinical trial is planned to commence in early 2024 in Guadalajara and Mexico City with approval from Mexico’s Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) anticipated in early 2025. Following approval from COFEPRIS, NuView plans to immediately request U.S. Food and Drug Administration (FDA) reciprocal recognition of NV-VPAC1™ Liquid Biopsy Diagnostic Test for commercial use in the United States.

About NV-VPAC1™

NuView's technology, branded NV-VPAC1™, consists of a small molecule peptide construct that targets the vasoactive intestinal peptide receptor type 1 (VPAC1), a part of the G protein-coupled receptor family. The VPAC1 receptor becomes highly overexpressed on the cell surface of a variety of cancers including brain, breast, lung, bladder, prostate, cervical, and colon. Attaching a molecular imaging or therapeutic passenger to NV-VPAC1 enables NuView to develop a precisely targeted approach that has been used in clinical studies for the diagnosis and treatment of cancer.

About NuView Life Sciences, Inc

NuView Life Sciences, Inc. ("NuView") is a Park City, Utah-based, precision radiopharmaceutical company seeking to revolutionize the global oncology market with its novel targeted technology, NV-VPAC1™, a first-of-its-kind, binary diagnostic platform engineered to bind with over-expressed VPAC1 receptors on the surface of a variety of cancer cells at the onset of oncogenesis. NuView is leveraging its NV-VPAC1™ platform to advance a pipeline of precision in vitro laboratory diagnostics tests and in vivo cancer diagnostics and therapy delivery systems targeting multiple high-need, large-market indications, including prostate and bladder cancer. To learn more, visit www.nuviewlifesciences.com

NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer

Wed, 05 Oct 2022 10:04:00 GMT

Developing a Novel Approach for the Future of Breast Cancer Diagnosis and Treatment

PARK CITY, UT / ACCESSWIRE / October 5, 2022 / NuView Life Sciences, Inc (“NuView”, the “company”), is a clinical stage precision oncology company focusing on innovative approaches, such as theranostics, to diagnose and treat cancer. The field of theranostics, combines molecular imaging (PET, PET/CT, PET/MRI) with targeted radionuclide therapy, which involves the use of small molecules, peptides, and/or antibodies for targeted delivery of therapeutic radionuclides. The exponential, global expansion of theranostics in oncology stems from its potential to target and eliminate tumor cells with minimal adverse effects, resulting in a mechanism of action that differs distinctly from that of most other systemic therapies.

NuView is leveraging its clinical stage small molecule, NV-VPAC1, to advance its unique theranostic technology for precision diagnostics and targeted therapy. NV-VPAC1 binds directly to VPAC1 receptors found in high densities in breast cancer tumors. Since VPAC1 is overexpressed on estrogen-dependent and independent mechanisms of human breast cancer cells, NV-VPAC1 can target many different forms of breast cancer.

NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer

Wed, 05 Oct 2022 10:04:00 GMT

Developing a Novel Approach for the Future of Breast Cancer Diagnosis and Treatment

Targeting VPAC1 Receptors for Imaging Glioblastoma

Tue, 25 Jan 2022 19:39:00 GMT

Targeting VPAC1 Receptors for Imaging Glioblastoma

NuView Life Sciences

NuView Life Sciences Creates Subsidiary for Latin American Market

Wed, 17 Nov 2021 13:00:00 GMT

Introducing a New Approach to Diagnose and Treat Cancer

PARK CITY, UT / ACCESSWIRE / November 17, 2021/ – NuView Life Sciences, Inc (“NuView”, the “company”), a clinical-stage oncology company focusing on innovative approaches to diagnose and treat cancers establishes NuView LATAM (“NV-LATAM”) in Mexico City.

Due to the COVID pandemic, many potential advances in healthcare research and development were postponed, especially clinical trials. As the healthcare system now begins to normalize, patients are returning to their healthcare practitioners and specialty doctors for routine checkups and preventative care. Healthcare companies focusing on developing innovative treatments are once again investing in their research and development efforts. Given the current worldwide concern for health, attention is also being directed on how to deliver healthcare innovation into new geographic markets.

With this backdrop, NuView has established a presence in Latin America called NV-LATAM. The purpose of NV-LATAM is to further the company’s clinical trials in Mexico City to diagnose cancer and offer a targeted therapeutic approach.

“NV-LATAM is introducing a modern approach to cancer identification and treatment based on molecular expressions found on the surface of cancer cells for a variety of malignancies,” said Dr. Robert Maroon, Chief Executive Officer of NV-LATAM will start by submitting an in vitro genitourinary lab assay application with intent of receiving approval from COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), Mexico’s federal agency in charge of overseeing and approving medical devices. NV-LATAM believes that NuView’s NV-VPAC1 will offer a novel approach to identifying cancer and provide significant benefits for patients, physicians, and the national healthcare system.”

Paul Crowe, Chairman and Chief Executive Officer of NuView, remarked, “NuView’s mission is to enhance the way that cancer is discovered and treated utilizing the technology invented by Dr. Mathew Thakur and later applied to liquid biopsy diagnostic applications by Dr. Mathew Thakur and Dr. Leonard Gomella at Thomas Jefferson University . Our intent is to address the patient’s wellbeing as well as to assist the physicians in the sensitive task of identifying cancer and treating patients. We are especially pleased to be expanding into new markets, specifically Latin America.”

NuView’s NV-VPAC1 is a versatile platform technology that can potentially be utilized for preclinical and clinical studies for a variety of cancers including: brain, breast, lung, bladder, prostate, cervical, and colon. Further updates related to these additional clinical indications as well as its entry into other geographic markets will be forthcoming.

About NuView Life Sciences, Inc

Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of our technology, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

Corporate Contact

Sherri Fitch
NuView Life Sciences, Inc
1389 Center Drive, Suite 200
Park City, Utah 84098
Office: +1.435.647.9758
E-mail: admin@nuviewlifesciences.com

Investor/Media Contact
Jennifer K. Zimmons, PhD, MBA
President
Zimmons International Communications, Inc.
Phone: +1.917.214.3514
E-mail: jzimmons@zimmonsic.com

# # #

NuView Life Sciences Creates Subsidiary for Latin American Market

NuView Life Sciences

Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics

Sun, 28 Feb 2021 23:40:00 GMT

Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics

NuView Life Sciences

Oncology Firm Develops Test for Potential Pediatric Cancers Diagnoses

Mon, 08 Feb 2021 20:59:00 GMT

Oncology Firm Develops Test for Potential Pediatric Cancers Diagnoses

NuView Life Sciences

Delfi Diagnostics reels in $100M for blood-based cancer test

Wed, 20 Jan 2021 02:13:00 GMT

Delfi Diagnostics reels in $100M for blood-based cancer test

NuView Life Sciences

Radiopharmaceuticals Are Showing Promise as the Next Generation of Cancer Treatment

Mon, 18 Jan 2021 00:44:00 GMT

Recent major investments signal growth in an emerging therapeutic sector.

Radiopharmaceuticals Are Showing Promise as the Next Generation of Cancer Treatment

NuView Life Sciences

NuView Life Sciences Develops New Theranostics Approach to Offset High Cost of Cancer Diagnosis, Treatment

Mon, 16 Nov 2020 16:32:00 GMT

NuView Life Sciences Develops New Theranostics Approach to Offset High Cost of Cancer Diagnosis, Treatment

NuView Life Sciences

Radiopharmaceuticals Gain Traction for Cancer Theranostics Potential

Thu, 12 Nov 2020 16:25:00 GMT

After decades of neglect from big pharma, radiopharmaceuticals are generating major oncology deals globally. This could lead to a boom in cancer drugs that can serve as both treatments and diagnostics, or ‘theranostics.’

Over the last several months, there has been big activity from companies developing drugs that use radioactivity to destroy tumors. Just this week, we’ve seen the Australian firm Telix Pharmaceuticals licensing its portfolio to China Grand Pharma in a deal worth €242M (AU $400M). Not long after a €182M ($212M) IPO in June, the US-based Fusion Pharma was recently recruited by the big pharma AstraZeneca to co-develop radiotherapies for cancer. And in mid-October, the US radiopharmaceuticals startup RayzeBio launched with a €39M ($45M) Series A .

“ The market is clearly hot at the moment and, whilst the majority of the investment has been in the US, we are also seeing a high level of interest and activity in Europe and the Far East, ” said Paul Edwards, NanoMab’s CEO.

—more—

Cancer Theranostics Potential

Radiopharmaceuticals Gain Traction for Cancer Theranostics Potential

NuView Life Sciences

Molecular theranostics: prostate cancer and neuroendocrine tumor treatment gets personal

Wed, 03 Jun 2020 16:53:00 GMT

Prostate cancer is far more prevalent than neuroendocrine tumors. The American Cancer Society estimates that there will be about 161,360 new cases of prostate cancer and about 26,730 deaths from the disease this year.

“When talking about prostate cancer that recurs and becomes hormone resistant, you have to lock all of the hormones in the body, which is usually done with medication, but even with these medications the tumors reoccur,” says Czernin.

The prostate-specific membrane antigen (PSMA) protein, which is found on the surface of prostate cancer and metastatic cells, was first discovered in the 1980s. It was originally labeled with Ga-68 and only used for diagnostic purposes, but eventually it was labeled with Lu-177 to also be used to treat metastatic prostate cancer.

…more…

Molecular theranostics: prostate cancer and neuroendocrine tumor treatment gets personal

NuView Life Sciences

VIP/PACAP, and their receptors and cancer

Fri, 29 May 2020 01:17:00 GMT

Abstract
Purpose of review—To summarize the roles of VIP/PACAP and their receptors(VPAC1, VPAC2/PAC1) in human tumors as well as their role in potential novel treatments.

Recent findings—Considerable progress has been made in understanding of the effects of VIP/ PACAP on growth of various tumors as well as in the signaling cascades involved, especially of the role of transactivation of the Epidermal growth factor(EGF) family. The overexpression of VPAC1/2, PAC1 on a number of common neoplasms (breast, lung, prostate, CNS, neuroblastoma) is receiving increased attention both as a means of tumor imaging the location and extent of these tumors, as well as for targeted directed treatment, by coupling cytotoxic agents to VIP/PACAP analogues.

Summary—VIP/PACAP has prominent growth effects on a number of common neoplasms, which frequently overexpressed the three subtypes of their receptors. The increased understanding of their signaling cascades, effect on tumor growth/differentiation, and the use of the overexpression of these receptors for localization/targeted cytotoxic delivery, are all suggesting possible novel tumor treatments.

News | Press Releases | NuView Life Sciences | NuView Life Sciences

Targeting genomic VPAC receptors in voided urine for confirmation of benign prostatic hyperplasia

NuView Announces Two Appointments to Board of Directors

NuView Life Sciences Announces the Appointments of Dr. Stanley J. Pappelbaum and A.J. Boechler to Board of Directors ﻿

NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer

NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer

Targeting VPAC1 Receptors for Imaging Glioblastoma

NuView Life Sciences Creates Subsidiary for Latin American Market

Introducing a New Approach to Diagnose and Treat Cancer

Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics

Oncology Firm Develops Test for Potential Pediatric Cancers Diagnoses

Delfi Diagnostics reels in $100M for blood-based cancer test

Radiopharmaceuticals Are Showing Promise as the Next Generation of Cancer Treatment

NuView Life Sciences Develops New Theranostics Approach to Offset High Cost of Cancer Diagnosis, Treatment

Radiopharmaceuticals Gain Traction for Cancer Theranostics Potential

Cancer Theranostics Potential

Molecular theranostics: prostate cancer and neuroendocrine tumor treatment gets personal

VIP/PACAP, and their receptors and cancer

NuView Life Sciences Announces the Appointments of Dr. Stanley J. Pappelbaum and A.J. Boechler to Board of Directors